Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Update

Monopar Therapeutics Inc. (NASDAQ:MNPR) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 22,000 shares, a decrease of 18.2% from the November 15th total of 26,900 shares. Approximately 0.7% of the company’s stock are short sold. Based on an average trading volume of 1,240,000 shares, the short-interest ratio is currently 0.0 days.

Monopar Therapeutics Stock Up 5.2 %

NASDAQ:MNPR traded up $1.32 during trading hours on Monday, hitting $26.70. 57,667 shares of the company traded hands, compared to its average volume of 636,153. The company has a market cap of $140.92 million, a PE ratio of -12.88 and a beta of 1.23. The firm’s 50-day simple moving average is $15.94 and its 200-day simple moving average is $7.89. Monopar Therapeutics has a one year low of $1.54 and a one year high of $38.50.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.09. As a group, equities research analysts expect that Monopar Therapeutics will post -1.65 EPS for the current year.

Insiders Place Their Bets

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan purchased 1,550 shares of the firm’s stock in a transaction on Monday, October 28th. The stock was acquired at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the purchase, the chief financial officer now owns 1,550 shares of the company’s stock, valued at $25,187.50. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 34.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on MNPR shares. Rodman & Renshaw started coverage on shares of Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 target price for the company. HC Wainwright lifted their price target on Monopar Therapeutics from $6.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 11th.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.